Last reviewed · How we verify

Alkeran — Competitive Intelligence Brief

Alkeran (melphalan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating Drug. Area: Oncology.

marketed Alkylating Drug Oncology Live · refreshed every 30 min

Target snapshot

Alkeran (melphalan) — Apotex.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Alkeran TARGET melphalan Apotex marketed Alkylating Drug 1964-01-01
Pepaxto MELPHALAN FLUFENAMIDE Oncopeptides Ab marketed Alkylating Drug 2021-01-01
Zepzelca LURBINECTEDIN Jazz Pharmaceuticals marketed Alkylating Drug [EPC] 2020-01-01
Yondelis TRABECTEDIN Janssen Prods marketed Alkylating Drug [EPC] Proto-oncogene tyrosine-protein kinase Src 2015-01-01
Treanda BENDAMUSTINE Baxter marketed Alkylating Drug Histone deacetylase 6 2008-01-01
Temodar temozolomide Merck & Co. marketed Alkylating Drug [EPC] 1999-01-01
Hexalen ALTRETAMINE Eisai marketed Alkylating Drug Cytochrome P450 1A2 1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Alkylating Drug class)

  1. · 1 drug in this class
  2. Apotex · 1 drug in this class
  3. Avet Lifesciences · 1 drug in this class
  4. Baxter · 1 drug in this class
  5. Eisai · 1 drug in this class
  6. Leadiant Biosci Inc · 1 drug in this class
  7. Oncopeptides Ab · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alkeran — Competitive Intelligence Brief. https://druglandscape.com/ci/melphalan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: